Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 8/20 | 0.43 |
| ▸ | NOS1 | P29475 | 8/20 | 0.43 |
| ▸ | NOS3 | P29474 | 6/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL27468620 | 1.00 | OTC (0.44) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL25212883 | 0.97 | OTC (0.47) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL4586460 | 0.97 | OTC (0.47) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL4586458 | 0.97 | OTC (0.47) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL28224753 | 0.95 | OTC (0.41) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL3496886 | 0.94 | KMT2A (0.47) | OTCNOS2NOS1NOS3SLC7A5 | |
| Arginine SCHEMBL5544129 | 0.93 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL9754275 | 0.93 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL1821002 | 0.93 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5312506 | 0.93 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666842-B2 | Elastin peptide analogs and uses thereof | Connective Tissue Imagineering, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1998790-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007100874-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | CONNECTIVE TISSUE IMAGINEERING LLC. | 2005-03-17 | — | — | US | disclosed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | ELANE, CUTA, ENPEP | OTC 1356/4885NOS2 1743/4885NOS1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.